Benzimidazoles Downregulate Mdm2 and MdmX and Activate p53 in MdmX Overexpressing Tumor Cells
Open accessThe DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
Tumor suppressor p53 is mutated in about 50% of cancers. Most malignant melanomas carry wild-type p53, but p53 activity is often inhibited due to overexpression of its negative regulators Mdm2 or MdmX. We performed high throughput screening of 2448 compounds on A375 cells carrying p53 activity luciferase reporter construct to reveal compounds that promote p53 activity in melanoma. Albendazole and fenbendazole, two approved and commonly used benzimidazole anthelmintics, stimulated p53 activity and were selected for further studies. The protein levels of p53 and p21 increased upon the treatment with albendazole and fenbendazole, indicating activation of the p53–p21 pathway, while the levels of Mdm2 and MdmX decreased in melanoma and breast cancer cells overexpressing these proteins. We also observed a reduction of cell viability and changes of cellular morphology corresponding to mitotic catastrophe, i.e., G2/M cell cycle arrest of large multinucleated cells with disrupted microtubules. In summary, we established a new tool for testing the impact of small molecule compounds on the activity of p53 and used it to identify the action of benzimidazoles in melanoma cells. The drugs promoted the stability and transcriptional activity of wild-type p53 via downregulation of its negative regulators Mdm2 and MdmX in cells overexpressing these proteins. The results indicate the potential for repurposing the benzimidazole anthelmintics for the treatment of cancers overexpressing p53 negative regulators.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Oncoprotein MDM2 is a ubiquitin ligase E3 for tumor suppressor p53
Honda, R., Tanaka, H., & Yasuda, H. (1997) · FEBS Letters · doi:10.1016/s0014-5793(97)01480-4 · Cited by 1,951 · cited 1×
“Mdm2 serves as an E3 ubiquitin ligase that targets p53 for proteasome-mediated degradation [3].”
BackgroundMDM2, MDMX and p53 in oncogenesis and cancer therapy
Wade, M., Li, Y.-C., & Wahl, G. M. (2013) · Nature Reviews Cancer · doi:10.1038/nrc3430 · Cited by 1,279 · cited 1×
“Amplification or overexpression of Mdm2 and MdmX occur in a wide range of tumors, including malignant melanoma [5].”
BackgroundModes of action of anthelmintic drugs
Martin, R. J. (1997) · The Veterinary Journal · doi:10.1016/s1090-0233(05)80005-x · Cited by 538 · cited 3×
“The mechanism of ABZ action includes not only the microtubule inhibition but also the blockage of glucose uptake and generation of ROS, leading to low cellular levels of ATP [15] and DNA damage [16,17], respectively.”
BackgroundMDM4 is a key therapeutic target in cutaneous melanoma
Gembarska, A., Luciani, F., Fedele, C., Russell, E. A., Dewaele, M., Villar, S., Zwolinska, A., Haupt, S., de Lange, J., Yip, D., et al. (2012) · Nature Medicine · doi:10.1038/nm.2863 · Cited by 327 · cited 1×
“Notably, MdmX overexpression was detected in approximately 65% of melanomas in stages I–IV [6].”
BackgroundMDM2 and MDM4: p53 regulators as targets in anticancer therapy
Toledo, F., & Wahl, G. M. (2007) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2007.03.022 · Cited by 261 · cited 1×
“Additionally, its function is abrogated by the overexpression of Mdm2 and MdmX in a significant proportion of tumors retaining wild-type p53 [1,2].”
BackgroundMebendazole Induces Apoptosis via Bcl-2 Inactivation in Chemoresistant Melanoma Cells
Doudican, N., Rodriguez, A., Osman, I., & Orlow, S. J. (2008) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-07-2159 · Cited by 152 · cited 1×
“demonstrated that mebendazole selectively induces Bcl2-mediated apoptosis in melanoma cells but not in melanocytes [24].”
BackgroundIn vitro and in vivo suppression of growth of hepatocellular carcinoma cells by albendazole
Pourgholami, M. H., Woon, L., Almajd, R., Akhter, J., Bowery, P., & Morris, D. L. (2001) · Cancer Letters · doi:10.1016/s0304-3835(01)00382-2 · Cited by 139
Albendazole as a promising molecule for tumor control
Castro, L. S. E. P. W., Kviecinski, M. R., Ourique, F., Parisotto, E. B., Grinevicius, V. M. A. S., Correia, J. F. G., Wilhelm Filho, D., & Pedrosa, R. C. (2016) · Redox Biology · doi:10.1016/j.redox.2016.09.013 · Cited by 81
Albendazole sensitizes cancer cells to ionizing radiation
Patel, K., Doudican, N. A., Schiff, P. B., & Orlow, S. J. (2011) · Radiation Oncology · doi:10.1186/1748-717x-6-160 · Cited by 66
Ghasemi, F., Black, M., Vizeacoumar, F., Pinto, N., Ruicci, K. M., Le, C. C. S. H., Lowerison, M. R., Leong, H. S., Yoo, J., Fung, K., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.17292 · Cited by 38 · cited 2×
“Antiproliferative activity of ABZ and other benzimidazoles was described in a broad spectrum of cancer cell lines such as hepatocellular [18], colorectal [19], human HPV-negative HNSCC [23], Molecules 2019, 24, 2152 9 of 14 as well as in melanoma cell lines.”
Background
Cited by
The Antitumor Potentials of Benzimidazole Anthelmintics as Repurposing Drugs
Son, D.-S., Lee, E.-S., & Adunyah, S. E. (2020) · Immune Network · doi:10.4110/in.2020.20.e29 · Cited by 130
Nath, J., Paul, R., Ghosh, S. K., Paul, J., Singha, B., & Debnath, N. (2020) · Life Sciences · doi:10.1016/j.lfs.2020.118189 · Cited by 71
Repurposing of Benzimidazole Anthelmintic Drugs as Cancer Therapeutics
Song, B., Park, E. Y., Kim, K. J., & Ki, S. H. (2022) · Cancers · doi:10.3390/cancers14194601 · Cited by 55
Anti-cancer effects of fenbendazole on 5-fluorouracil-resistant colorectal cancer cells
Park, D., Lee, J.-H., & Yoon, S.-P. (2022) · The Korean Journal of Physiology & Pharmacology · doi:10.4196/kjpp.2022.26.5.377 · Cited by 23
Metadata
- Authors
- Mrkvová, Z., Uldrijan, S., Pombinho, A., Bartůněk, P., & Slaninová, I.
- Venue
- Molecules
- Publisher
- MDPI AG
- Published
- 2019-06-07
- Volume
- 24
- Issue
- 11
- Pages
- 2152
- ISSN
- 1420-3049 (ISSN-L)
- OpenAlex
- W2948115989
- Cited by
- 33
- References
- 10
- FWCI
- 1.45
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Benzimidazoles Downregulate Mdm2 and MdmX and Activate p53 in MdmX Overexpressing Tumor Cells. https://app.cochat.ai/papers/10.3390/molecules24112152
- The paper
- Mrkvová, Z., Uldrijan, S., Pombinho, A., Bartůněk, P., & Slaninová, I. (2019). Benzimidazoles Downregulate Mdm2 and MdmX and Activate p53 in MdmX Overexpressing Tumor Cells. Molecules. https://doi.org/10.3390/molecules24112152
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.